Released Nov 5, 2020, after the close
10-Q filed Nov 5, 2020, 36 days after period end · 0001564590-20-051301
Q3 2020 · 10-Q
Revenue$7.56M$7.56M +211.2% vs Q3 2019+38.3% vs Q2 2020
Net Income-$58.68M-$58.68M N/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.68-$0.68 N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$31,487,000N/M
Operating Cash Flowderived-$30,733,000N/M
Free Cash Flowderived-$31,687,000N/M
Margins · derived
Operating margin-416.6%+699.9 pt vs Q3 2019
Net margin-776.4%+319.0 pt vs Q3 2019
What the release said
The release
Same quarter
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $7.56M | $2.43M | $1.03M | $1.03M |
| Net Income | -$58.68M | -$26.61M | -$16.78M | -$10.68M |
| EPS Diluted | -$0.68 | -$0.40 | -$0.31 | -$0.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR